X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare PLETHICO PHARMA with ALEMBIC LTD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs ALEMBIC LTD - Comparison Results

ALEMBIC LTD 
   Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA ALEMBIC LTD PLETHICO PHARMA/
ALEMBIC LTD
 
P/E (TTM) x -1.1 51.1 - View Chart
P/BV x 0.0 2.2 0.8% View Chart
Dividend Yield % 0.0 0.5 -  

Financials

 PLETHICO PHARMA   ALEMBIC LTD
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
ALEMBIC LTD
Mar-18
PLETHICO PHARMA/
ALEMBIC LTD
5-Yr Chart
Click to enlarge
High Rs39572 548.5%   
Low Rs3134 92.3%   
Sales per share (Unadj.) Rs604.44.7 12,858.0%  
Earnings per share (Unadj.) Rs32.56.1 532.1%  
Cash flow per share (Unadj.) Rs51.36.2 821.8%  
Dividends per share (Unadj.) Rs00.20 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs473.640.7 1,164.6%  
Shares outstanding (eoy) m34.08267.03 12.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.411.3 3.1%   
Avg P/E ratio x6.68.7 75.6%  
P/CF ratio (eoy) x4.28.5 49.0%  
Price / Book Value ratio x0.51.3 34.6%  
Dividend payout %03.3 0.0%   
Avg Mkt Cap Rs m7,26214,139 51.4%   
No. of employees `000NANA-   
Total wages/salary Rs m1,596207 769.5%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m20,5981,255 1,641.0%  
Other income Rs m386370 104.4%   
Total revenues Rs m20,9841,625 1,291.0%   
Gross profit Rs m2,818111 2,536.1%  
Depreciation Rs m64238 1,699.2%   
Interest Rs m1,5932 93,717.6%   
Profit before tax Rs m969442 219.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m01,212 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-13824 -577.8%   
Profit after tax Rs m1,1071,630 67.9%  
Gross profit margin %13.78.9 154.5%  
Effective tax rate %-14.35.4 -263.6%   
Net profit margin %5.4129.8 4.1%  
BALANCE SHEET DATA
Current assets Rs m18,8771,867 1,011.0%   
Current liabilities Rs m11,896591 2,012.2%   
Net working cap to sales %33.9101.6 33.3%  
Current ratio x1.63.2 50.2%  
Inventory Days Days3694 38.1%  
Debtors Days Days19874 269.0%  
Net fixed assets Rs m9,8611,791 550.6%   
Share capital Rs m341534 63.8%   
"Free" reserves Rs m12,33110,324 119.4%   
Net worth Rs m16,13910,858 148.6%   
Long term debt Rs m4,70641 11,421.8%   
Total assets Rs m33,14611,591 286.0%  
Interest coverage x1.6260.9 0.6%   
Debt to equity ratio x0.30 7,684.4%  
Sales to assets ratio x0.60.1 573.8%   
Return on assets %8.114.1 57.9%  
Return on equity %6.915.0 45.7%  
Return on capital %12.315.2 80.9%  
Exports to sales %21.41.5 1,382.9%   
Imports to sales %15.221.0 72.6%   
Exports (fob) Rs m4,40219 22,692.8%   
Imports (cif) Rs m3,136263 1,190.9%   
Fx inflow Rs m4,40219 22,692.8%   
Fx outflow Rs m3,184264 1,206.8%   
Net fx Rs m1,219-244 -498.5%   
CASH FLOW
From Operations Rs m2,437236 1,033.7%  
From Investments Rs m-6,265-224 2,796.7%  
From Financial Activity Rs m2,490-27 -9,361.3%  
Net Cashflow Rs m-1,337-15 9,034.9%  

Share Holding

Indian Promoters % 82.7 64.0 129.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.3 0.2 2,150.0%  
FIIs % 5.5 9.7 56.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 7.5 26.1 28.7%  
Shareholders   10,665 54,701 19.5%  
Pledged promoter(s) holding % 85.7 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  FULFORD INDIA  ALKEM LABORATORIES  AJANTA PHARMA  

Compare PLETHICO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 190 Points Higher; Consumer Durable and Healthcare Stocks Witness Buying(Closing)

After trimming sharp losses in the afternoon session, Indian share markets continued to witness buying interest and ended the day on a positive note.

Related Views on News

ALEMBIC LTD Announces Quarterly Results (2QFY19); Net Profit Up 4.0% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, ALEMBIC LTD has posted a net profit of Rs 294 m (up 4.0% YoY). Sales on the other hand came in at Rs 336 m (up 3.1% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY19); Net Profit Up 106.9% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, ALEMBIC LTD has posted a net profit of Rs 69 m (up 106.9% YoY). Sales on the other hand came in at Rs 445 m (up 50.4% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA 5-YR ANALYSIS

COMPARE PLETHICO PHARMA WITH

MARKET STATS